INDICATIONS AND USAGE（适应症）

Metastatic Colorectal Cancer

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Metastatic Gastric Cancer

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

DOSAGE（服用剂量）

The recommended dosage of LONSURF is 35 mg/m2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment.

Instruct patients to swallow LONSURF tablets whole.

Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.

ADVERSE REACTIONS（不良反应）

Anemia

Neutropenia

Asthenia/fatigue

Nausea

Thrombocytopenia

Decreased appetite

Diarrhea

Vomiting

Abdominal pain

Pyrexia

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/f5beed22-d71d-4c0d-8dca-2c7317d65d85/spl-doc?hl=Lonsurf

朗斯福information